Insmed (MEX:INSM) Total Liabilities: MXN24,723 Mil (As of Mar. 2026)

What is Insmed Total Liabilities?

Insmed MEX:INSM 68 Total Liabilities is MXN24,723 Mil as of Mar. 2026. GuruFocus rates MEX:INSM with a GF Score™ of 68/100 and a GF Value™ of MXN5,773.42. The stock has 4 warning signs investors should review.

Insmed's Total Liabilities for the quarter that ended in Mar. 2026 was MXN24,723 Mil.

Insmed's quarterly Total Liabilities increased from Sep. 2025 (MXN25,960.07 Mil) to Dec. 2025 (MXN27,469.17 Mil) but then declined from Dec. 2025 (MXN27,469.17 Mil) to Mar. 2026 (MXN24,723.03 Mil).

Insmed's annual Total Liabilities increased from Dec. 2023 (MXN28,207.13 Mil) to Dec. 2024 (MXN36,285.83 Mil) but then declined from Dec. 2024 (MXN36,285.83 Mil) to Dec. 2025 (MXN27,469.17 Mil).

Insmed Total Liabilities Related Terms

Insmed Total Liabilities Historical Data

* Premium members only.

The historical data trend for Insmed's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insmed Total Liabilities Chart

Insmed Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

17,088.98

30,579.16

28,207.13

36,285.83

27,469.17

Insmed Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															34,852.10	23,162.21	25,960.07	27,469.17	24,723.03

68GF Score

Insmed Inc MEX:INSM

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Insmed Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Insmed's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8442.405	+	(10332.697	+	8694.07
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	27,469

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	40774.952	-	13305.78
	=	27,469

Insmed's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	6509.949	+	(10312.396	+	7900.685
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	24,723

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	37433.415	-	12710.385
	=	24,723

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of MXN24,723 Mil mean?

Insmed (MEX:INSM) has a Total Liabilities of MXN24,723 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Insmed and its competitors.

Is Insmed's Total Liabilities too high?

Insmed's current Total Liabilities is MXN24,723 Mil. Overall, Insmed has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.

How does Insmed's Total Liabilities compare to INCY and BNTX?

Insmed's Total Liabilities of MXN24,723 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Insmed and its competitors. Insmed's current Total Liabilities is MXN24,723 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Insmed stock overvalued right now?

Insmed (MEX:INSM) has a current Total Liabilities of MXN24,723 Mil. The stock's GF Value™ is MXN5,773.42, compared to a current price of MXN3,760.00 — trading 34.9% below its estimated fair value. The current Total Liabilities is MXN24,723 Mil. Insmed's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Insmed (MEX:INSM), the current Total Liabilities is MXN24,723 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insmed (MEX:INSM) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of MXN3,760.00 is trading 34.9% below its estimated GF Value™ of MXN5,773.42.

Key valuation signals for MEX:INSM:

Total Liabilities: MXN24,723 Mil
GF Value™: MXN5,773.42 vs. price of MXN3,760.00 (34.9% below fair value)
GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the MEX:INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insmed Business Description

Industry Healthcare Biotechnology

Comparable Companies INCY BNTX ROIV RPRX MRNA ASND ONC JAZZ BBIO EXEL VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD XKRX:068270 HKSE:02269

Other Exchanges INSM:USA 1INSM:Italy 0JAV:UK IM8N:Germany

Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807

Website https://www.insmed.com

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

68GF Score

Get the complete analysis for MEX:INSM

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,760.00

Price

MXN5,773.42

GF Value

View MEX:INSM Analysis

See Total Liabilities data for all stocks →